HUTCHMED (China) Limited vs Dynavax Technologies Corporation: Annual Revenue Growth Compared

Biotech Revenue Growth: HUTCHMED vs. Dynavax (2014-2023)

__timestampDynavax Technologies CorporationHUTCHMED (China) Limited
Wednesday, January 1, 20141103200091813000
Thursday, January 1, 20154050000178203000
Friday, January 1, 201611043000216080000
Sunday, January 1, 2017327000241203000
Monday, January 1, 20188198000214109000
Tuesday, January 1, 201935219000204890000
Wednesday, January 1, 202046551000227976000
Friday, January 1, 2021439442000356128000
Saturday, January 1, 2022722683000426409000
Sunday, January 1, 2023232284000837999000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotech Giants: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and innovation. Over the past decade, HUTCHMED (China) Limited and Dynavax Technologies Corporation have showcased contrasting trajectories in their annual revenue growth.

From 2014 to 2023, HUTCHMED's revenue surged by approximately 813%, reflecting its robust expansion and strategic market positioning. In contrast, Dynavax experienced a more volatile journey, with a remarkable peak in 2022, where its revenue was nearly 66 times higher than in 2014, before a significant drop in 2023.

This comparison highlights the diverse challenges and opportunities within the biotech sector, emphasizing the importance of adaptability and innovation. As these companies continue to evolve, their revenue trends offer valuable insights into the broader industry landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025